Journal Summary - Discover more summaries and articles from M3 India

Journal Summaries

General Medicine

Dermatology

Ritlecitinib and brepocitinib phase 2a randomized trial results review for alopecia areata treatment

Journal of the European Academy of Dermatology and Venereology | Jan 28, 2022 Dermatology

Efficacy and safety of pimecrolimus 1% vs sertaconazole 2% in facial seborrheic dermatitis treatment

Clinical and Experimental Dermatology | Jan 28, 2022 Dermatology

Real-life impact of the immunological tests to predict relapse after treatment cessation in patients with bullous pemphigoid: A French multicenter retrospective study

Journal of the American Academy of Dermatology | Jan 27, 2022 Dermatology

Efficacy of ablative fractional carbon dioxide laser combined with autologous platelet‐rich plasma vs ablative fractional carbon dioxide laser and placebo in the treatment of striae gravidarum: A randomized clinical trial

Journal of Cosmetic Dermatology | Jan 27, 2022 Dermatology

Risk of all-cause mortality, CVD mortality, and cancer mortality in bullous pemphigoid

JAMA | Jan 06, 2022 Dermatology

Long-term risk of skin cancer and lymphoma in users of topical tacrolimus and pimecrolimus: Final results from the extension of the cohort study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE)

Clinical Epidemiology | Jan 06, 2022 Dermatology

Trial of spesolimab for generalized pustular psoriasis

New England Journal of Medicine | Jan 05, 2022 Dermatology

Improvement of mortality prognostication in patients with epidermal necrolysis: The role of novel inflammatory markers and proposed revision of SCORTEN (Re-SCORTEN)

JAMA | Jan 05, 2022 Dermatology

Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: Placebo-controlled, randomized, phase III clinical trial (ECZTRA 7)

British Journal of Dermatology | Jan 05, 2022 Dermatology

Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: Results from two phase III, long-term studies

British Journal of Dermatology | Dec 26, 2021 Dermatology

« Prev 1 2 3 4 5 … 113 Next »

Ritlecitinib and brepocitinib phase 2a randomized trial results review for alopecia areata treatment

Efficacy and safety of pimecrolimus 1% vs sertaconazole 2% in facial seborrheic dermatitis treatment

Real-life impact of the immunological tests to predict relapse after treatment cessation in patients with bullous pemphigoid: A French multicenter retrospective study

Efficacy of ablative fractional carbon dioxide laser combined with autologous platelet‐rich plasma vs ablative fractional carbon dioxide laser and placebo in the treatment of striae gravidarum: A randomized clinical trial

Risk of all-cause mortality, CVD mortality, and cancer mortality in bullous pemphigoid

Long-term risk of skin cancer and lymphoma in users of topical tacrolimus and pimecrolimus: Final results from the extension of the cohort study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE)

Trial of spesolimab for generalized pustular psoriasis

Improvement of mortality prognostication in patients with epidermal necrolysis: The role of novel inflammatory markers and proposed revision of SCORTEN (Re-SCORTEN)

Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: Placebo-controlled, randomized, phase III clinical trial (ECZTRA 7)

Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: Results from two phase III, long-term studies

Micronutrient Deficiencies in The Modern Diet: Causes & Correction

Age Related Macular Degeneration

Managing Polypharmacy in Elderly Patients

'Weekend Warrior' Trend: Health Perks for Busy Physicians

Pulmonary Embolism: MCQs Challenge

Ritlecitinib and brepocitinib phase 2a randomized trial results review for alopecia areata treatment

Efficacy and safety of pimecrolimus 1% vs sertaconazole 2% in facial seborrheic dermatitis treatment

Real-life impact of the immunological tests to predict relapse after treatment cessation in patients with bullous pemphigoid: A French multicenter retrospective study

Efficacy of ablative fractional carbon dioxide laser combined with autologous platelet‐rich plasma vs ablative fractional carbon dioxide laser and placebo in the treatment of striae gravidarum: A randomized clinical trial

Risk of all-cause mortality, CVD mortality, and cancer mortality in bullous pemphigoid

Long-term risk of skin cancer and lymphoma in users of topical tacrolimus and pimecrolimus: Final results from the extension of the cohort study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE)

Trial of spesolimab for generalized pustular psoriasis

Improvement of mortality prognostication in patients with epidermal necrolysis: The role of novel inflammatory markers and proposed revision of SCORTEN (Re-SCORTEN)

Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: Placebo-controlled, randomized, phase III clinical trial (ECZTRA 7)

Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: Results from two phase III, long-term studies

Micronutrient Deficiencies in The Modern Diet: Causes & Correction

Age Related Macular Degeneration

Managing Polypharmacy in Elderly Patients

'Weekend Warrior' Trend: Health Perks for Busy Physicians

Pulmonary Embolism: MCQs Challenge

Select Specialty

Select Topic